Michael D. Beauvais


  • JD, Georgetown University Law Center, 1999; Student Editor-in-Chief of The Tax Lawyer , the American Bar Association's official journal on taxation
  • BA, cum laude, College of the Holy Cross, 1996


  • Massachusetts
  • American Bar Association
  • American Health Lawyers Association
  • Boston Bar Association

Michael regularly contributes to a variety of publications and conferences on current trends in the life sciences industry, securities, HIT, general corporate and healthcare regulatory matters, and has also been a faculty member of CLE programs on these topics. Michael is also a member of the Boston Bar Association’s Health Law section, where he currently serves as the Co-chair of the Social Action Committee and is a member of the Steering Committee.

  • The Best Lawyers in America (2018-2021)
  • Legal 500 (2014, 2017-2018, 2020)
  • Massachusetts Super Lawyers – Rising Stars (2014)

Michael D. Beauvais


Michael Beauvais, the immediate past global co-chair of the life sciences and health care industry group, has more than 21 years of experience representing clients in the pharmaceutical, biotechnology, medical device, digital health and health care services industries. His transactional experience spans a broad range of mergers and acquisitions, public and private securities offerings, financings, collaborations, and other commercial transactions.

Michael also regularly counsels private equity firms, financial sponsors and other strategic investors in the life sciences and health care industries on matters pertaining to their investments.


  • Representation of Bain Capital in its partnership with Pfizer to create a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system.
  • Representation of a global private investment firm in its acquisition of a leading global life sciences investment firm that has raised $2.6 billion since its founding.
  • Representation of Genstar Capital in its acquisition of Bracket, a leading clinical trial technology and pharmaceutical services provider.
  • Representation of Vapotherm, Inc., a medical technology company focused on the development and commercialization of technologies to treat respiratory distress, in its $56 million initial public offering.
  • Representation of a global leading alternative investment firm in a series of transactions, including:
    • its $55 million Series D financing and investment round for a German biopharmaceutical company.
    • its $70 million convertible preferred PIPE investment in a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics.
    • its $830 million acquisition of a controlling stake in a South Korean pharmaceutical company.
    • its strategic investment in a leading provider of cloud-based claims management and patient payment solutions for physician practices and hospitals and subsequent definitive agreement to combine with another company to become the leading provider of revenue cycle management.
  • Representation of a private equity firm in its $450 million acquisition of a clinical services and clinical technology solutions provider for various clinical trials.
  • Representation of a behavioral health care company in its acquisition of a psychological services company.
  • Representation of a public medical device company in multiple acquisitions, both domestically and internationally.
  • Representation of a public biotechnology company in the divestiture of multiple divisions, including genetic testing, laboratory, and diagnostics.
  • Representation of a public healthcare services company in connection with the acquisition and divesture of multiple independent living and skilled nursing facilities.
  • Representation of a genomic research institution in its collaboration with sequencing technology company.
  • Representation of a public hospital company in the divestiture of a hospital system and ancillary providers.
  • Representation of the largest private dental practice management company in the United States in the sale of a controlling interest to a private equity firm.
  • Representation of a leading children’s hospital in connection with a strategic affiliation.
  • Representation of Oxford Immunotec Global PLC (UK) in its initial public offering on a U.S. exchange.
  • Lead counsel to the underwriters in connection with initial public offerings by Connecture, Medidata, athenahealth, MedAssets and Synta Pharmaceuticals.



  • Speaker, “Navigating Digital Health Investments and the Dealmaking Landscape,” Ropes & Gray and Life Sciences Executives network webinar (September 2, 2020)
  • JD, Georgetown University Law Center, 1999; Student Editor-in-Chief of The Tax Lawyer , the American Bar Association's official journal on taxation
  • BA, cum laude, College of the Holy Cross, 1996
Cookie Settings